Auris Medical Holding AG (NASDAQ:EARS) shares saw an uptick in trading volume on Thursday . 73,585 shares were traded during trading, a decline of 6% from the previous session’s volume of 77,925 shares.The stock last traded at $3.68 and had previously closed at $3.65.

Several brokerages recently issued reports on EARS. Leerink Swann restated a “buy” rating on shares of Auris Medical Holding AG in a research report on Thursday, May 12th. Zacks Investment Research upgraded Auris Medical Holding AG from a “hold” rating to a “buy” rating and set a $4.50 price objective for the company in a research report on Tuesday. Finally, Jefferies Group restated a “buy” rating on shares of Auris Medical Holding AG in a research report on Friday, June 10th.

The firm’s market capitalization is $125.64 million. The firm’s 50-day moving average is $3.84 and its 200 day moving average is $4.10.

Auris Medical Holding AG (NASDAQ:EARS) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by $0.04. During the same quarter in the prior year, the business posted ($0.28) EPS. Analysts anticipate that Auris Medical Holding AG will post ($1.01) earnings per share for the current fiscal year.

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.